Featured Research

from universities, journals, and other organizations

New class of drug targets heart disease

Date:
September 17, 2013
Source:
University of Alberta
Summary:
Researchers have created a drug that replaces key peptide linked with heart failure, diabetes and high blood pressure.

Researchers at the University of Alberta have developed a synthetic peptide that could be the first in a new class of drugs to treat heart disease, high blood pressure and diabetes.

Researchers at the U of A found that a deficiency in the peptide apelin is associated with heart failure, pulmonary hypertension and diabetes. They also developed a synthetic version that targets pathways in the heart and promotes blood vessel growth.

Lead author Gavin Oudit, an associate professor in the Faculty of Medicine & Dentistry, said the synthetic form of apelin is far more stable and potent than the naturally occurring peptide, making drug therapies possible.

"It's a new group of drugs that we hope can be used for a wide variety of disorders, all of which have a huge economic burden on the health-care system," said Oudit, a cardiologist and clinician-scientist at the Mazankowski Alberta Heart Institute.

Oudit's research group studied apelin deficiency in the hearts of mice and humans through the Human Explanted Heart Program, or HELP. The HELP program allows for the study of specimens obtained from patients undergoing a heart transplant.

The research team found that hearts from patients who suffered heart attacks were deficient in apelin, which is needed for angiogenesis -- the formation of new blood vessels that helps the body adapt after tissue damage from heart attacks.

Oudit's team has filed a provisional patent on the synthetic apelin and will continue work developing the drug to be more potent and clinically applicable. Once the drug is perfected, they'll move into the first phase of clinical trials in two to three years.

Oudit said the breakthrough could not have happened without the contributions of U of A colleagues, including John Vederas, a medicinal chemist and professor in the Department of Chemistry, and Allan Murray, a clinician-scientist and nephrologist in the Department of Medicine. Wang Wang and Shaun McKinnie, both PhD students in Oudit's and Vederas's laboratories, also played a key role in this discovery.

"Having this kind of environment that's multidisciplinary and collaborative is absolutely critical to take a discovery to the next level," Oudit said. "We showed this kind of translational work can be done here, in Edmonton, at the University of Alberta."


Story Source:

The above story is based on materials provided by University of Alberta. Note: Materials may be edited for content and length.


Journal Reference:

  1. W. Wang, S. M. K. McKinnie, V. B. Patel, G. Haddad, Z. Wang, P. Zhabyeyev, S. K. Das, R. Basu, B. McLean, V. Kandalam, J. M. Penninger, Z. Kassiri, J. C. Vederas, A. G. Murray, G. Y. Oudit. Loss of Apelin Exacerbates Myocardial Infarction Adverse Remodeling and Ischemia-reperfusion Injury: Therapeutic Potential of Synthetic Apelin Analogues. Journal of the American Heart Association, 2013; 2 (4): e000249 DOI: 10.1161/JAHA.113.000249

Cite This Page:

University of Alberta. "New class of drug targets heart disease." ScienceDaily. ScienceDaily, 17 September 2013. <www.sciencedaily.com/releases/2013/09/130917113306.htm>.
University of Alberta. (2013, September 17). New class of drug targets heart disease. ScienceDaily. Retrieved August 23, 2014 from www.sciencedaily.com/releases/2013/09/130917113306.htm
University of Alberta. "New class of drug targets heart disease." ScienceDaily. www.sciencedaily.com/releases/2013/09/130917113306.htm (accessed August 23, 2014).

Share This




More Health & Medicine News

Saturday, August 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Newsy (Aug. 21, 2014) An experimental drug used to treat Marburg virus in rhesus monkeys could give new insight into a similar treatment for Ebola. Video provided by Newsy
Powered by NewsLook.com
Two US Ebola Patients Leave Hospital Free of the Disease

Two US Ebola Patients Leave Hospital Free of the Disease

AFP (Aug. 21, 2014) Two American missionaries who were sickened with Ebola while working in Liberia and were treated with an experimental drug are doing better and have left the hospital, doctors say on August 21, 2014. Duration: 01:05 Video provided by AFP
Powered by NewsLook.com
Cadavers, a Teen, and a Medical School Dream

Cadavers, a Teen, and a Medical School Dream

AP (Aug. 21, 2014) Contains graphic content. He's only 17. But Johntrell Bowles has wanted to be a doctor from a young age, despite the odds against him. He was recently the youngest participant in a cadaver program at the Indiana University NW medical school. (Aug. 21) Video provided by AP
Powered by NewsLook.com
American Ebola Patients Released: What Cured Them?

American Ebola Patients Released: What Cured Them?

Newsy (Aug. 21, 2014) It's unclear whether the American Ebola patients' recoveries can be attributed to an experimental drug or early detection and good medical care. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins